IL321935A - Treatment of cd20-positive b-cell lymphoma with obituzumab - Google Patents
Treatment of cd20-positive b-cell lymphoma with obituzumabInfo
- Publication number
- IL321935A IL321935A IL321935A IL32193525A IL321935A IL 321935 A IL321935 A IL 321935A IL 321935 A IL321935 A IL 321935A IL 32193525 A IL32193525 A IL 32193525A IL 321935 A IL321935 A IL 321935A
- Authority
- IL
- Israel
- Prior art keywords
- obinutuzumab
- hour
- administration
- cycle
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Claims (15)
1. [Claim 1] Claims A pharmaceutical composition for treating CD20-positive B-cell lymphoma comprising obinutuzumab, which is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;
2. [Claim 2] (b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour. The pharmaceutical composition according to claim 1, wherein a duration per administration in the second or later cycle is within 180
3. [Claim 3] minutes, preferably within 150 minutes, more preferably within 120minutes, the most preferably within 90 minutes.The pharmaceutical composition according to claim 1 or 2, which is ad- ministered 3 times in the first cycle, and once a cycle in the second or
4. [Claim 4]later cycle.The pharmaceutical composition according to claim 3, wherein the first administration in the first cycle is initiated at a speed of 50 mg of obin- utuzumab an hour, and the second or later administration in the first
5. [Claim 5]cycle is initiated at a speed of 100 mg of obinutuzumab an hour.The pharmaceutical composition according to any one of claims 1 to 4, wherein the administration speed in the second or later cycle is increased to 700 mg of obinutuzumab an hour or faster, preferably to 800 mg of obinutuzumab an hour or faster, more preferably up to 9mg of obinutuzumab an hour.
6. [Claim 6] The pharmaceutical composition according to any one of claims 1 to 5, wherein, in (b), the pharmaceutical composition is given according to at least one of the following (c) to (e) conditions:(c) if no infusion reaction of Grade 3 or above appeared with the last three administrations, and the number of lymphocytes in peripheral blood before administration is less than 5000/uL, administration is carried out at 100 mg/hour for 30 minutes. If no infusion reaction is 20 WO 2019/017499 PCT/JP2018/038924 observed all that time, the speed can be increased to 900 mg/hour. Depending on the condition of the patient, the speed is decreased to, for example, the administration speed in cycle 1, as appropriate.(d) if an infusion reaction of Grade 1/2 appeared, administration is restarted at half the speed before administration was stopped. If no infusion reaction is observed in 30 minutes, the speed can be increased to 900 mg/hour.(e) if an infusion reaction of Grade 3, administration is restarted at 2mg/hour or lower. If no infusion reaction is observed in 30 minutes, the speed can be increased by 50 mg/hour every 30 minutes to a maximum of 400 mg/hour.
7. [Claim 7] The pharmaceutical composition according to any one of claims 1 to 6, which is administered on days 1, 8 and 15 in the first cycle, and on day in the second or later cycle.
8. [Claim 8] The pharmaceutical composition according to any one of claims 1 to 7, wherein each cycle is 3 weeks.
9. [Claim 9] The pharmaceutical composition according to any one of claims 1 to 7, which is used in combination with at least one of other anti-tumor agents, and whose administration cycle is synchronized with a dosing cycle of said at least one of other anti-tumor agents, wherein the dosing cycle is 4 weeks a cycle.
10. [Claim 10] The pharmaceutical composition according to claim 9, wherein said at least one of other anti-tumor agents is selected from CHOP, CVP, ben- damustine, fludarabine, lenalidomide, an anti-PD-1 antibody, and an anti-PD-Ll antibody.
11. [Claim 11] The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is given every two months for two years as maintenance monotherapy after said two or more cycles.
12. [Claim 12] The pharmaceutical composition according to any one of claims 1 to 11, wherein the obinutuzumab concentration in infusion fluid when in- travenously drip infused is 10 to 40 mg/mL, preferably 20 to 30 mg/ mL, more preferably 25 mg/mL.
13. [Claim 13] The pharmaceutical composition according to any one of claims 1 to 12, further comprising a trehalose hydrate, L-histidine, L-histidine hy- drochloride hydrate, or polyoxyethylene (160) polyoxypropylene (30) glycol as an additive.
14. [Claim 14] Use of obinutuzumab in a manufacture of a pharmaceutical com- 21 WO 2019/017499 PCT/JP2018/038924 position for treating CD20-positive B-cell lymphoma comprising obin- utuzumab, wherein the composition is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;(b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour.
15. [Claim 15] A method for treating CD20-positive B-cell lymphoma by a pharma-ceutical composition comprising obinutuzumab, wherein the com- position is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles:(a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour;(b) the maximum administration speed in the second or later cycle is equal to or more than 700 mg of obinutuzumab an hour, preferably equal to or more than 800 mg of obinutuzumab an hour, more preferably equal to or more than 900 mg of obinutuzumab an hour.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574297P | 2017-10-19 | 2017-10-19 | |
| PCT/JP2018/038924 WO2019017499A2 (en) | 2017-10-19 | 2018-10-19 | A pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321935A true IL321935A (en) | 2025-09-01 |
Family
ID=64362606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273909A IL273909B2 (en) | 2017-10-19 | 2018-10-19 | Treatment of CD20-positive B-cell lymphoma with obinutuzumab |
| IL321935A IL321935A (en) | 2017-10-19 | 2018-10-19 | Treatment of cd20-positive b-cell lymphoma with obituzumab |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273909A IL273909B2 (en) | 2017-10-19 | 2018-10-19 | Treatment of CD20-positive B-cell lymphoma with obinutuzumab |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12129304B2 (en) |
| EP (2) | EP3697818B1 (en) |
| JP (2) | JP6860652B2 (en) |
| KR (3) | KR20260011191A (en) |
| CN (2) | CN111212854A (en) |
| AU (2) | AU2018303836B2 (en) |
| BR (1) | BR112020007731A2 (en) |
| CA (1) | CA3079374A1 (en) |
| ES (1) | ES3005784T3 (en) |
| IL (2) | IL273909B2 (en) |
| MX (2) | MX419643B (en) |
| PL (1) | PL3697818T3 (en) |
| TW (2) | TWI828593B (en) |
| WO (1) | WO2019017499A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3697818T3 (en) * | 2017-10-19 | 2025-03-24 | F. Hoffmann-La Roche Ag | Treatment of CD20-positive B-cell lymphoma with obinutuzumab |
| AU2020356896B2 (en) * | 2019-10-04 | 2026-07-30 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| WO2023042679A1 (en) | 2021-09-17 | 2023-03-23 | キヤノン株式会社 | Power transmission device and power reception device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038955T2 (en) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| RS63364B1 (en) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | THERAPEUTIC COMBINATIONS OF BTK INHIBITORS, PD-1 INHIBITORS AND/OR PD-L1 INHIBITORS |
| US11149091B2 (en) * | 2015-12-09 | 2021-10-19 | Cedars-Sinai Medical Center | Methods for treating nephrotic syndrome |
| CN108395482B (en) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof |
| US12377681B2 (en) | 2017-07-21 | 2025-08-05 | The Yokohama Rubber Co., Ltd. | Pneumatic tire |
| PL3697818T3 (en) * | 2017-10-19 | 2025-03-24 | F. Hoffmann-La Roche Ag | Treatment of CD20-positive B-cell lymphoma with obinutuzumab |
-
2018
- 2018-10-19 PL PL18804720.3T patent/PL3697818T3/en unknown
- 2018-10-19 ES ES18804720T patent/ES3005784T3/en active Active
- 2018-10-19 BR BR112020007731-3A patent/BR112020007731A2/en unknown
- 2018-10-19 IL IL273909A patent/IL273909B2/en unknown
- 2018-10-19 TW TW112120572A patent/TWI828593B/en active
- 2018-10-19 WO PCT/JP2018/038924 patent/WO2019017499A2/en not_active Ceased
- 2018-10-19 MX MX2020003418A patent/MX419643B/en unknown
- 2018-10-19 EP EP18804720.3A patent/EP3697818B1/en active Active
- 2018-10-19 CN CN201880067120.XA patent/CN111212854A/en not_active Withdrawn
- 2018-10-19 CN CN202511095071.9A patent/CN120983618A/en active Pending
- 2018-10-19 AU AU2018303836A patent/AU2018303836B2/en active Active
- 2018-10-19 CA CA3079374A patent/CA3079374A1/en active Pending
- 2018-10-19 JP JP2019508989A patent/JP6860652B2/en active Active
- 2018-10-19 KR KR1020257043253A patent/KR20260011191A/en active Pending
- 2018-10-19 KR KR1020207014191A patent/KR102766089B1/en active Active
- 2018-10-19 US US16/756,057 patent/US12129304B2/en active Active
- 2018-10-19 TW TW107137033A patent/TWI805630B/en active
- 2018-10-19 EP EP24213649.7A patent/EP4520347A3/en active Pending
- 2018-10-19 IL IL321935A patent/IL321935A/en unknown
- 2018-10-19 KR KR1020247035575A patent/KR102906969B1/en active Active
-
2020
- 2020-07-13 MX MX2024009217A patent/MX2024009217A/en unknown
-
2021
- 2021-03-26 JP JP2021052571A patent/JP7370357B2/en active Active
-
2024
- 2024-09-23 US US18/893,101 patent/US20250026847A1/en active Pending
-
2025
- 2025-07-15 AU AU2025205481A patent/AU2025205481A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511072A5 (en) | ||
| RU2018120377A (en) | PRE-FILLED PHARMACEUTICAL PACKING CONTAINING A LIQUID COMPOSITION BASED ON VEGF ANTAGONIST | |
| JP7491220B2 (en) | Cancer treatment in combination with immune checkpoint inhibitors and FOLFIRINOX therapy | |
| IL263110B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| HRP20230504T1 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| JP2019514974A5 (en) | ||
| JP2018520094A5 (en) | ||
| JP2010515709A5 (en) | ||
| CN108601831A (en) | Use of an anti-PD-1 antibody combined with a VEGFR inhibitor in the preparation of a drug for treating cancer | |
| CN102006875A (en) | Use of picoplatin and bevacizumab to treat colorectal cancer | |
| EP4549467A2 (en) | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer | |
| IL273909B1 (en) | Treatment of CD20-positive B-cell lymphoma with obinutuzumab | |
| RU2020134307A (en) | MELFLUFENE DOSING REGIMES FOR CANCER | |
| JP2025508786A5 (en) | ||
| JP2021152002A5 (en) | ||
| TW202227089A (en) | Combination therapy for the treatment of pik3ca mutant cancer | |
| JP2023539625A5 (en) | ||
| JP2022501332A5 (en) | ||
| JP2017527551A5 (en) | ||
| Kim et al. | Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer | |
| Wolf et al. | Peripheral administration of antithymocyte globulins: a review of current literature | |
| CN102327599A (en) | Be used to treat the compositions and the method for myelodysplastic syndrome | |
| Cohn | Prevention strategies for mycobacterium avium-intracellulare complex (MAC) infection: A review of recent studies in patients with AIDS | |
| JP2020172471A (en) | Pharmaceutical composition containing humanized anti-human CD26 antibody | |
| Starr | Isatuximab plus RVd Combination Achieves High Rates of No MRD in Patients with Multiple Myeloma. |